A Novel Treatment for Symptomatic Heart Failure

The only direct treatment for high left atrial pressures (LAP)

Corvia Atrial Shunt

The Corvia Atrial Shunt is a novel, minimally invasive cardiac implant for patients suffering from Heart Failure with Preserved Ejection Fraction (HFpEF) or Mid-Range Ejection Fraction (HFmrEF). Designed to reduce elevated LAP, the primary contributor to HF symptoms, the Corvia Atrial Shunt offers the most advanced therapeutic option for HF patients with an EF≥40%.

The Corvia Atrial Shunt is the most widely studied interatrial shunt for heart failure. It has been implanted in nearly 500 patients worldwide, and more than 40 patients have had the shunt for over 5 years.1

Dynamic Decompression

Atrial shunting safely relieves the high pressures that cause HF symptoms by connecting the two upper chambers of the heart. This connection allows the heart to dynamically decompress by directing blood from the left to right atrium on demand, thereby reducing HF symptoms during activity.


The Corvia Atrial Shunt is implanted via a minimally invasive procedure. During this procedure, an interventional cardiologist or electrophysiologist inserts a catheter (small tube) in a vein near the groin to access the heart. This catheter is then used to create a very small passage in the heart wall between the right and left atria where the shunt is placed. The newly created passage allows blood to flow from the high pressure left atrium to the lower pressure right atrium. As a result, the pressure in the left side of the heart and the lungs decreases, and heart failure symptoms are reduced.


By facilitating continuous and dynamic decompression of the left atrium, the Corvia Atrial Shunt is intended to reduce heart failure hospitalizations and improve heart failure symptoms and quality of life.2,3

  1. Unpublished data on file at Corvia Medical.
  2. Feldman T, Mauri L, Kahwash, et al. Transcatheter Interatrial Shunt Device for the Treatment of Heart Failure With Preserved Ejection Fraction (REDUCE LAP-HF I): A Phase 2, Randomized, Sham-Controlled Trial. Circ. 2018;137(4):364-375.
  3. Kaye D, Hasenfuß G, Neuzil P, et al. One-Year Outcomes After Transcatheter Insertion of an Interatrial Shunt Device for the Management of Heart Failure With Preserved Ejection Fraction. Circ Heart Fail. 2016;9(12):e003662.